Addus HomeCare stock gets a USD 137.00 target from Raymond James
Published on 09/30/2026 at 07:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAddus HomeCare Corporation (ISIN US0067391062) was at EUR 100.00 in pre-market trading at Lang & Schwarz on September 30, 2026 at 7:39 a.m. CEST, plus 0.25 percent versus the prior close of EUR 99.75. The latest analyst action gives the home-care provider a fresh valuation reference as it prepares to integrate a sizable personal-care acquisition.
Raymond James sets USD 137.00 target
Investing.com reported on September 28, 2026 that Raymond James initiated coverage with an Outperform rating and a USD 137.00 price target. The firm left its estimates unchanged pending further details on the transaction and third-quarter results, making execution rather than a fresh earnings revision the immediate issue.
Bank of America supplies a more cautious counterpoint. MarketBeat reported on September 14, 2026 that BofA kept a Neutral rating while cutting its target from USD 140.00 to USD 125.00. The split between the two targets highlights the market's focus on acquisition execution and organic growth.
AccentCare deal adds scale
Addus agreed to acquire AccentCare's personal care and community care business outside New York for an anticipated cash purchase price of USD 275.0 million. The transaction covers operations serving an average daily census of 13,700 customers and is expected to add USD 280.0 million in annualized personal-care revenue, according to the StockTitan summary of the September 14, 2026 filing.
The deal is subject to regulatory approvals and customary closing conditions. Funding is planned through a combination of Addus' revolver and cash on hand, so the transaction increases the growth opportunity while also making balance-sheet discipline important.
Q2 revenue reaches USD 377.40 million
For the quarter ended June 30, 2026, Addus reported net service revenue of USD 377.40 million, up 8.00 percent from the prior-year quarter, with diluted GAAP EPS of USD 1.49. Adjusted diluted EPS was USD 1.73 versus a USD 1.70 consensus estimate, while operating cash flow reached USD 40.01 million, figures summarized by StockTitan from the August 3, 2026 filing.
The revenue comparison and the adjusted EPS beat give the acquisition a stronger operating base, but the deal's contribution depends on its closing and integration. Addus' market capitalization was USD 2.1 billion as of September 29, 2026, while its 52-week range was USD 87.95 to USD 124.44.
ADUS stock price before Xetra opens
Addus HomeCare stock was at EUR 100.00 at Lang & Schwarz on September 30, 2026 at 7:39 a.m. CEST, plus 0.25 percent against the prior close of EUR 99.75. The NASDAQ-listed company has its next earnings date listed as November 2, 2026 by GetSignal.
Addus HomeCare stock facts
- Company: Addus HomeCare Corporation
- ISIN: US0067391062
- Ticker: ADUS
- Primary exchange: NASDAQ
- Price Lang & Schwarz (as of September 30, 2026, 7:39 a.m. CEST): EUR 100.00
- Change versus prior close: plus 0.25 percent
- Prior close Lang & Schwarz (September 29, 2026): EUR 99.75
- Market capitalization: USD 2.1 billion (as of September 29, 2026)
- 52-week range: USD 87.95-124.44 (as of September 29, 2026)
- Sector / Industry: Healthcare / Medical Care Facilities
- Next earnings date: November 2, 2026
